BRAF and melanoma: Although this is still debated, Del Bianco et al. recently showed that in a cohort of BRAF-mutated melanoma patients who received MAPK inhibitors, those with the −146C > T mutation showed a significantly worse PFS compared to those carrying the −124C > T mutation and a two-fold increased risk of progression [24].